GlaxoSmithKline Plc: Deep Value or Dud?

Are GlaxoSmithKline Plc (LON:GSK) shares worth holding onto or better avoided?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Large cap pharma is somewhat of a minefield for investors at the moment. Patent expiries are exposing sector leaders to competition from generics, drug development pipelines running thin and and require extensive investment or M&A, while many firms are also locked into expensive dividend commitments.

GlaxoSmithKline (LSE: GSK) fits the above bill perfectly, as it is pressured on all fronts with patent expiries, generic competition and price pressures each encroaching upon earnings.

And all this is while the number of new approvals it has pending sits at just two, and management remains locked into a progressive dividend policy that could become a liability if the group’s performance deteriorates by any notable measure in the coming quarters.

To be clear, GSK will need to put this year’s projected contraction behind it and get back to earnings growth if it is to cover its dividend commitments 1x over when 2016/17 comes around.  

The devil’s in the details

The competition facing GSK’s Advair — a treatment for asthma and chronic obstructive pulmonary disease — is already hotting up and could get worse still in 2016 when generics begin to make their way into developed markets and Glaxo’s remaining Advair patent ( the Diskus inhaler) expires.

Advair has accounted for 20% of group sales and the income from this product has already fallen by 22% in the US (Q1 2015), as health care bill payers have begun to favour cheaper alternatives.

The US is a market that is yet to feel the impact of generics and if the current situation in India with Cipla provides any indication of what we can expect the US business to look like when they do appear, then the future could be bleak for both Advair and GSK.  

Why hold?

On a more positive note, GSK’s HIV products performed well, with sales of new drugs Tivicay and Triumeq reaching £294m, which is significantly ahead of estimates.

These types of results make it unlikely that management will make another attempt to dispose of ViiV Healthcare in the near term, which is important, given that projections for combined sales of roughly £2.5 billion by 2017 mean that the group is in with a chance at offsetting the impact of Advair’s decline.

In addition, the R&D day that GSK is holding for investors in November could see management unveil some improvements in the development pipeline, which would be welcomed by investors and will probably help boost sentiment toward the shares.

Furthermore, management has been frustratingly slow in its  progress toward a leaner cost structure which, while disappointing to date, implies that there is still scope for belated progress to boost the bottom line here.

Deep value or dud?

The answer to this question probably depends a great deal upon what management have to say at the up and coming investor day in November.

If the group is able to unveil meaningful progress in advanced clinical trials across key areas such as HIV, Cardio, Respiratory or Oncology, preferably to an extent where it is almost ready to file for approvals, then management will probably be vindicated and the value case for the shares strengthened.

However, if Glaxo cannot bring anything meaningful to the table in November, then it is probable that investors will remain uninspired, that the shares could continue to perform poorly, and that attention within the analyst community could soon begin to focus upon the viability of the dividend from 2016/17 onwards.

If I had to make a call, I’d say that, it probably won’t hurt to hang onto the shares if already invested, at least for the foreseeable future — even if only for the current yield. For prospective new buyers, Glaxo may make a good long term play for those who are blessed with plenty of patience and the required time horizon.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Skinner has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »